english.prescrire.org > Spotlight > 100 most recent > Selinexor (Nexpovio°) in relapsed or refractory multiple myeloma: not acceptable

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Selinexor (Nexpovio°) in relapsed or refractory multiple myeloma: not acceptable

 Marketing Authorisations   For patients with relapsed or refractory multiple myeloma, various combinations of antineoplastic drugs extend survival. Selinexor, an exportin-1 inhibitor, has been authorised in the European Union for use in multiple myeloma: in combination with bortezomib and dexamethasone after at least one line of treatment; and in combination with dexamethasone after at least four lines of treatment.
Full article available for download by subscribers (3 pages)

©Prescrire 1 September 2024

Source: "Selinexor (Nexpovio°) in relapsed or refractory multiple myeloma" Prescrire Int 2024; 33 (262): 201-203. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
See also:

"Adding daratumumab
(Darzalex°) in relapsed or
refractory multiple myeloma"
Prescrire Int 2023;
32 (253): 268-269.
Subscribers only

"Relapsed or refractory
multiple myeloma"
Prescrire Int 2021;